Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Lymphoma, Myeloma & Leukemia

• Publication date

  2017-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clml.2017.06.021PMID 28743429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

  2017cited by this paper
• Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS

  2017cited by this paper
• Precision medicine needs randomized clinical trials

  2017cited by this paper
• Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

  2017cited by this paper
• Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma

  2017cited by this paper
• Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)

  2017cited by this paper
• A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.

  2017cited by this paper
• CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model.

  2017cited by this paper
• A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

  2016cited by this paper
• Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

  2016cited by this paper
• Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium

  2016cited by this paper
• A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax

  2016cited by this paper
• PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation

  2016cited by this paper
• Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma

  2016cited by this paper
• Ethical, Legal, and Social Implications of Personalized Genomic Medicine Research: Current Literature and Suggestions for the Future.

  2016cited by this paper
• Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

  2016cited by this paper
• Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

  2016cited by this paper
• B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma

  2016cited by this paper
• Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.

  2016cited by this paper
• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

  2016cited by this paper
• Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Exerts Dose-Dependent Cytostatic and Cytocidal Effects on Multiple Myeloma Cells Via Autophagy

  2016cited by this paper
• T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

  2016cited by this paper
• Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

  2016cited by this paper
• Treating cancer with selective CDK4/6 inhibitors

  2016cited by this paper
• Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.

  2016cited by this paper
• Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

  2016cited by this paper
• Isocitrate dehydrogenase mutations in gliomas.

  2016cited by this paper
• Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

  2016cited by this paper
• Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

  2016cited by this paper
• Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

  2016cited by this paper
• Trends in overall survival and costs of multiple myeloma, 2000–2014

  2016cited by this paper
• Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)

  2015cited by this paper
• PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

  2015cited by this paper
• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

  2015cited by this paper
• BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

  2015cited by this paper
• NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

  2015cited by this paper
• Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

  2015cited by this paper
• Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

  2015cited by this paper
• Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

  2015cited by this paper
• Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

  2015cited by this paper
• Improved overall survival in melanoma with combined dabrafenib and trametinib.

  2015cited by this paper
• A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

  2015cited by this paper
• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

  2015cited by this paper
• Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

  2015cited by this paper
• Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation

  2015cited by this paper
• Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study

  2015cited by this paper
• Interim Analysis of the MMRF CoMMpass Study: Comprehensive Characterization of Multiple Myeloma Patients at Diagnosis Reveals Distinct Molecular Subtypes and Clinical Outcomes

  2015cited by this paper
• Precision medicine for cancer with next-generation functional diagnostics

  2015cited by this paper
• Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

  2015cited by this paper
• Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

  2015cited by this paper
• Inhibiting MEK in MAPK pathway-activated myeloma

  2015cited by this paper
• Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

  2015influential reference
• Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

  2014cited by this paper
• BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.

  2014cited by this paper
• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

  2014cited by this paper
• CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

  2014cited by this paper
• Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

  2014influential reference
• p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

  2014cited by this paper
• The Tao of myeloma.

  2014cited by this paper
• Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

  2014cited by this paper
• Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma

  2014cited by this paper
• Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis

  2014cited by this paper
• A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

  2013cited by this paper
• Implementing personalized cancer genomics in clinical trials

  2013cited by this paper
• Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

  2013cited by this paper
• Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

  2013cited by this paper
• The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

  2013cited by this paper
• Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

  2013cited by this paper
• Targeting the BRAF V600E mutation in multiple myeloma.

  2013cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

  2012cited by this paper
• Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway

  2012cited by this paper
• TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

  2012cited by this paper
• Progression of RAS-mutant leukemia during RAF inhibitor treatment.

  2012cited by this paper
• MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

  2012cited by this paper
• Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

  2012cited by this paper
• Transcriptional and epigenetic mechanisms of addiction

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• BRAF mutations in hairy-cell leukemia.

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

  2011cited by this paper
• Multiple myeloma.

  2011cited by this paper
• RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

  2011cited by this paper
• Big science: The cancer genome challenge

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

  2010influential reference
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

  2010cited by this paper
• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  2009cited by this paper
• Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

  2009cited by this paper
• Clinical and biological significance of RAS mutations in multiple myeloma

  2008cited by this paper
• Improved survival in multiple myeloma and the impact of novel therapies.

  2008cited by this paper
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008influential reference
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

  2007cited by this paper
• Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

  2006cited by this paper
• Analysis of PTEN deletions and mutations in multiple myeloma.

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• International staging system for multiple myeloma.

  2005cited by this paper
• Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma.

  2004cited by this paper
• CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

  2004cited by this paper

• Multiple Myeloma and Precursor Plasma Cell Disorders: From Emerging Driver Mutations to Current and Future Therapeutic Strategies

  2025cites this paper
• Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo

  2022cites this paper
• Validation of clinical‐grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly‐diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project

  2021cites this paper
• Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma

  2020cites this paper
• Opportunities and Challenges for Precision Personalized Therapy in Multiple Myeloma

  2019cites this paper
• Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development

  2019cites this paper
• Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies

  2018cites this paper
• Etude de l'implication de mécanismes épigénétiques dans la physiopathologie du myélome multiple et dans la différenciation plasmocytaire normale

  2018cites this paper